Blood-brain barrier disturbances in diabetes-associated dementia: Therapeutic potential for cannabinoids.

[1]  D. Bevan,et al.  Interplay between metalloproteinases and cell signalling in blood brain barrier integrity. , 2018, Histology and histopathology.

[2]  Shengdi Chen,et al.  Blood-Brain Barrier Disruption Induced Cognitive Impairment Is Associated With Increase of Inflammatory Cytokine , 2018, Front. Aging Neurosci..

[3]  Y. Sarne,et al.  Reversal of age-related cognitive impairments in mice by an extremely low dose of tetrahydrocannabinol , 2018, Neurobiology of Aging.

[4]  H. Al‐Salami,et al.  Blood-Brain Barrier Dysfunction Precedes Cognitive Decline and Neurodegeneration in Diabetic Insulin Resistant Mouse Model: An Implication for Causal Link , 2017, Front. Aging Neurosci..

[5]  A. Fenning,et al.  Δ9-Tetrahydrocannabinol Prevents Cardiovascular Dysfunction in STZ-Diabetic Wistar-Kyoto Rats , 2017, BioMed research international.

[6]  L. Cucullo,et al.  Blood-brain barrier disruption in diabetic mice is linked to Nrf2 signaling deficits: Role of ABCB10? , 2017, Neuroscience Letters.

[7]  Y. Persidsky,et al.  Blood Brain Barrier Injury in Diabetes: Unrecognized Effects on Brain and Cognition , 2017, Journal of Neuroimmune Pharmacology.

[8]  T. Ulas,et al.  A chronic low dose of Δ9-tetrahydrocannabinol (THC) restores cognitive function in old mice , 2017, Nature Medicine.

[9]  R. Cuomo,et al.  Cannabidiol restores intestinal barrier dysfunction and inhibits the apoptotic process induced by Clostridium difficile toxin A in Caco-2 cells , 2017, United European gastroenterology journal.

[10]  Ji-Eun Lee,et al.  Distinct Roles of Transcription Factors KLF4, Krox20, and Peroxisome Proliferator-Activated Receptor γ in Adipogenesis , 2016, Molecular and Cellular Biology.

[11]  B. Baban,et al.  Blood–brain barrier breakdown promotes macrophage infiltration and cognitive impairment in leptin receptor-deficient mice , 2016, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[12]  D. Yoo,et al.  Chronic type 2 diabetes reduces the integrity of the blood-brain barrier by reducing tight junction proteins in the hippocampus , 2016, The Journal of veterinary medical science.

[13]  N. Nagai,et al.  A Review of the Mechanisms of Blood-Brain Barrier Permeability by Tissue-Type Plasminogen Activator Treatment for Cerebral Ischemia , 2016, Front. Cell. Neurosci..

[14]  T. England,et al.  Cannabidiol protects an in vitro model of the blood–brain barrier from oxygen‐glucose deprivation via PPARγ and 5‐HT1A receptors , 2015, British journal of pharmacology.

[15]  S. Dhaliwal,et al.  Blood–brain barrier dysfunction developed during normal aging is associated with inflammation and loss of tight junctions but not with leukocyte recruitment , 2015, Immunity & Ageing.

[16]  Richard H Tuligenga.  Intensive glycaemic control and cognitive decline in patients with type 2 diabetes: a meta-analysis , 2015, Endocrine connections.

[17]  D. Yoo,et al.  Activation of microglia and induction of pro-inflammatory cytokines in the hippocampus of type 2 diabetic rats , 2014, Neurological research.

[18]  J. Mamo,et al.  Long-term probucol therapy continues to suppress markers of neurovascular inflammation in a dietary induced model of cerebral capillary dysfunction , 2014, Lipids in Health and Disease.

[19]  R. Laprairie,et al.  Anti‐inflammatory effects of cannabinoid CB2 receptor activation in endotoxin‐induced uveitis , 2014, British journal of pharmacology.

[20]  L. Mestre,et al.  Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A2A receptors , 2013, Neurobiology of Disease.

[21]  D. Ray,et al.  Partial recovery of the damaged rat blood–brain barrier is mediated by adherens junction complexes, extracellular matrix remodeling and macrophage infiltration following focal astrocyte loss , 2013, Neuroscience.

[22]  J. Mamo,et al.  Nutraceutical agents with anti-inflammatory properties prevent dietary saturated-fat induced disturbances in blood–brain barrier function in wild-type mice , 2013, Journal of Neuroinflammation.

[23]  A. Ergul,et al.  Cerebral Neovascularization and Remodeling Patterns in Two Different Models of Type 2 Diabetes , 2013, PloS one.

[24]  J. Martínez-Orgado,et al.  Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? , 2013, British journal of clinical pharmacology.

[25]  S. Dhaliwal,et al.  Probucol prevents blood–brain barrier dysfunction in wild‐type mice induced by saturated fat or cholesterol feeding , 2013, Clinical and experimental pharmacology & physiology.

[26]  V. Lam,et al.  Restoration of dietary-fat induced blood–brain barrier dysfunction by anti-inflammatory lipid-modulating agents , 2012, Lipids in Health and Disease.

[27]  I. Krizbai,et al.  Activation of Cannabinoid Receptor 2 Attenuates Leukocyte–Endothelial Cell Interactions and Blood–Brain Barrier Dysfunction under Inflammatory Conditions , 2012, The Journal of Neuroscience.

[28]  N. Schröder,et al.  Memory-rescuing effects of cannabidiol in an animal model of cognitive impairment relevant to neurodegenerative disorders , 2012, Psychopharmacology.

[29]  B. Zlokovic.  Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders , 2011, Nature Reviews Neuroscience.

[30]  C. Larochelle,et al.  How do immune cells overcome the blood–brain barrier in multiple sclerosis? , 2011, FEBS letters.

[31]  R. Swanson,et al.  Hyperglycemia promotes tissue plasminogen activator‐induced hemorrhage by Increasing superoxide production , 2011, Annals of neurology.

[32]  H. Luhmann,et al.  Caspase-3 Contributes to ZO-1 and Cl-5 Tight-Junction Disruption in Rapid Anoxic Neurovascular Unit Damage , 2011, PloS one.

[33]  S. Nam,et al.  Inflammation and Alzheimer’s disease , 2010, Archives of pharmacal research.

[34]  S. O'Sullivan,et al.  Pharmacological Effects of Cannabinoids on the Caco-2 Cell Culture Model of Intestinal Permeability , 2010, Journal of Pharmacology and Experimental Therapeutics.

[35]  Abigail M Polter,et al.  5-HT1A receptor-regulated signal transduction pathways in brain. , 2010, Cellular signalling.

[36]  J. Quevedo,et al.  Treatment with cannabidiol reverses oxidative stress parameters, cognitive impairment and mortality in rats submitted to sepsis by cecal ligation and puncture , 2010, Brain Research.

[37]  Z. Ackerman,et al.  Cannabidiol ameliorates cognitive and motor impairments in bile‐duct ligated mice via 5‐HT1A receptor activation , 2010, British journal of pharmacology.

[38]  Daniel Hoyer,et al.  Molecular biology of 5-HT receptors , 2008, Behavioural Brain Research.

[39]  J. Haorah,et al.  Activation of Peroxisome Proliferator-Activated Receptor γ (PPARγ) Suppresses Rho GTPases in Human Brain Microvascular Endothelial Cells and Inhibits Adhesion and Transendothelial Migration of HIV-1 Infected Monocytes1 , 2008, The Journal of Immunology.

[40]  I. Raz,et al.  Cannabidiol arrests onset of autoimmune diabetes in NOD mice , 2008, Neuropharmacology.

[41]  N. Stella,et al.  CB2 receptor‐mediated migration of immune cells: it can go either way , 2008, British journal of pharmacology.

[42]  L. Liaudet,et al.  Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption. , 2007, American journal of physiology. Heart and circulatory physiology.

[43]  B. T. Hawkins,et al.  Increased blood–brain barrier permeability and altered tight junctions in experimental diabetes in the rat: contribution of hyperglycaemia and matrix metalloproteinases , 2006, Diabetologia.

[44]  S. Ward,et al.  Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. , 2005, Gastroenterology.

[45]  Y. Khalifa,et al.  Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes. , 2005, The American journal of pathology.

[46]  R. Kesterson,et al.  Deletion of PPARγ in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistance , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[47]  Ralitza Gueorguieva,et al.  Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction , 2005, Biological Psychiatry.

[48]  D. Kendall,et al.  Vascular effects of delta 9-tetrahydrocannabinol (THC), anandamide and N-arachidonoyldopamine (NADA) in the rat isolated aorta. , 2005, European journal of pharmacology.

[49]  P. Soubrié,et al.  The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. , 2003, Molecular pharmacology.

[50]  Karen J. Ferguson,et al.  Willis on narcolepsy , 2003, Journal of neurology, neurosurgery, and psychiatry.

[51]  D. Andersson,et al.  Delta 9-tetrahydrocannabinol and cannabinol activate capsaicin-sensitive sensory nerves via a CB1 and CB2 cannabinoid receptor-independent mechanism. , 2002, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[52]  N. Kaminski,et al.  Examination of the immunosuppressive effect of delta9-tetrahydrocannabinol in streptozotocin-induced autoimmune diabetes. , 2001, International immunopharmacology.

[53]  T. Klockgether,et al.  Peroxisome Proliferator-Activated Receptor-γ Ligands Reduce Neuronal Inducible Nitric Oxide Synthase Expression and Cell DeathIn Vivo , 2000, The Journal of Neuroscience.

[54]  J. Olefsky.  Treatment of insulin resistance with peroxisome proliferator–activated receptor γ agonists , 2000 .

[55]  M. Feldmann,et al.  The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[56]  M. Elphick,et al.  Localisation of cannabinoid receptors in the rat brain using antibodies to the intracellular C‐terminal tail of CB1 , 2000, The Journal of comparative neurology.

[57]  S. Rivest,et al.  An Essential Role of Interleukin-1β in Mediating NF-κB Activity and COX-2 Transcription in Cells of the Blood–Brain Barrier in Response to a Systemic and Localized Inflammation But Not During Endotoxemia , 1999, The Journal of Neuroscience.

[58]  B. Schermer,et al.  Inhibition of the production of endothelium‐derived hyperpolarizing factor by cannabinoid receptor agonists , 1999, British journal of pharmacology.

[59]  B. Brouhard,et al.  Δ9 Tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells , 1998 .

[60]  M Toth,et al.  Increased anxiety of mice lacking the serotonin1A receptor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[61]  É. Mezey,et al.  Expression of the CB1 and CB2 receptor messenger RNAs during embryonic development in the rat , 1997, Neuroscience.

[62]  J. Auwerx,et al.  The Organization, Promoter Analysis, and Expression of the Human PPARγ Gene* , 1997, The Journal of Biological Chemistry.

[63]  E. Ellis,et al.  Anandamide and delta 9-THC dilation of cerebral arterioles is blocked by indomethacin. , 1995, The American journal of physiology.

[64]  G. Cabral,et al.  Delta 9-tetrahydrocannabinol inhibition of tumor necrosis factor-alpha: suppression of post-translational events. , 1993, The Journal of pharmacology and experimental therapeutics.

[65]  S. Munro,et al.  Molecular characterization of a peripheral receptor for cannabinoids , 1993, Nature.

[66]  M. Herkenham,et al.  Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[67]  Kosersky Ds.  Antihypertensive effects of delta9-tetrahydrocannabinol. , 1978 .

[68]  G. Cabral,et al.  Cannabinoids inhibit LPS‐inducible cytokine mRNA expression in rat microglial cells , 2000, Glia.

[69]  C. Halldin,et al.  Localization of 5-HT1A receptors in the living human brain using [carbonyl-11C]WAY-100635: PET with anatomic standardization technique. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[70]  M. Herkenham,et al.  Characterization and localization of cannabinoid receptors in brain: an in vitro technique using slide-mounted tissue sections. , 1991, NIDA research monograph.

[71]  Mara,et al.  High glucose induces DNA damage in cultured human endothelial cells. , 1986, The Journal of clinical investigation.

[72]  D. Kosersky.  Antihypertensive effects of delta9-tetrahydrocannabinol. , 1978, Archives internationales de pharmacodynamie et de therapie.